The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Edwards Lifesciences's revenues will expand 16.0% and EPS will grow 24.2%.
The average estimate for revenue is $499.1 million. On the bottom line, the average EPS estimate is $0.77.
Last quarter, Edwards Lifesciences logged revenue of $448.0 million. GAAP reported sales were 8.5% higher than the prior-year quarter's $412.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.58. GAAP EPS of $0.58 for Q3 were 35% higher than the prior-year quarter's $0.43 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 75.1%, 550 basis points better than the prior-year quarter. Operating margin was 21.1%, 660 basis points better than the prior-year quarter. Net margin was 15.4%, 290 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $1.89 billion. The average EPS estimate is $2.55.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 146 members out of 197 rating the stock outperform, and 51 members rating it underperform. Among 59 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 42 give Edwards Lifesciences a green thumbs-up, and 17 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Edwards Lifesciences is hold, with an average price target of $104.37.
Is Edwards Lifesciences the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Edwards Lifesciences to My Watchlist.